ARWR (Arrowhead Pharmaceuticals) EPS without NRI: $-2.23 (TTM As of Mar. 2026)


ARWR Arrowhead Pharmaceuticals Inc ARWR
49 GF Score
Price $83.98
GF Value $51.73
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals EPS without NRI?

Arrowhead Pharmaceuticals ARWR +4.41% 49 EPS without NRI is $-2.23 as of Mar. 2026. GuruFocus rates ARWR with a GF Score™ of 49/100 and a GF Value™ of $51.73 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,170 Biotechnology companies, Arrowhead Pharmaceuticals ranks better than 95.81% on this metric.

Arrowhead Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $-1.01. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.23.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 81.80% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 40.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Arrowhead Pharmaceuticals's EPS without NRI or its related term are showing as below:

ARWR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -163   Med: 4.5   Max: 81.8
Current: 81.8

During the past 13 years, Arrowhead Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 81.80% per year. The lowest was -163.00% per year. And the median was 4.50% per year.

ARWR's 3-Year EPS without NRI Growth Rate is ranked better than
95.81% of 1170 companies
in the Biotechnology industry
Industry Median: 16.75 vs ARWR: 81.80

Arrowhead Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.93. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.15.

Arrowhead Pharmaceuticals's EPS (Basic) for the three months ended in Mar. 2026 was $-0.93. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-2.15.


Arrowhead Pharmaceuticals  (NAS:ARWR) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Arrowhead Pharmaceuticals EPS without NRI Related Terms


Arrowhead Pharmaceuticals EPS without NRI Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals EPS without NRI Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.36 -1.67 -1.92 -5.00 -0.01

Arrowhead Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.75 -1.26 -0.18 0.22 -1.01

ARWR vs CYTK, TECH, KRYS: EPS without NRI Comparison

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arrowhead Pharmaceuticals PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's PE Ratio without NRI falls into.


ARWR
49GF Score
Arrowhead Pharmaceuticals Inc ARWR
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arrowhead Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-2.23 mean?
Arrowhead Pharmaceuticals (ARWR) has a EPS without NRI of $-2.23 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Arrowhead Pharmaceuticals and its competitors. According to the industry distribution chart, Arrowhead Pharmaceuticals ranks #49 out of 1170 companies in the Biotechnology industry, placing it in the top 4.2%.
Is Arrowhead Pharmaceuticals' EPS without NRI too high?
Arrowhead Pharmaceuticals' current EPS without NRI is $-2.23. Based on the distribution chart, Arrowhead Pharmaceuticals ranks #49 out of 1170 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' EPS without NRI compare to CYTK and TECH?
According to the Biotechnology industry distribution chart, Arrowhead Pharmaceuticals ranks #49 out of 1170 companies for EPS without NRI. This places Arrowhead Pharmaceuticals in the top 4% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.75, based on 1,170 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Arrowhead Pharmaceuticals and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arrowhead Pharmaceuticals's current EPS without NRI is $-2.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals (ARWR) is currently considered Significantly Overvalued. The stock's GF Value™ is $51.73, compared to a current price of $83.98 — trading 62.3% above its estimated fair value. The current EPS without NRI is $-2.23. Arrowhead Pharmaceuticals' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (ARWR), the current EPS without NRI is $-2.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arrowhead Pharmaceuticals (ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of $83.98 is trading 62.3% above its estimated GF Value™ of $51.73. GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ARWR:

  • EPS without NRI: $-2.23
  • GF Value™: $51.73 vs. price of $83.98 (62.3% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score

Get the complete analysis for ARWR

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$83.98
Price
$51.73
GF Value